Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psoriasis

- PMLiVE

Incyte’s Opzelura shows significant improvements in phase 3 vitiligo trial

The positive data has been published in The New England Journal of Medicine

Infographic: Therapy Watch Psoriasis

Our PsO infographic offers an introduction to the real-world patient insights collected by our Therapy Watch PsO study.

Research Partnership

- PMLiVE

It’s a Medscape wrap for #EADVCongress

Medscape was on-site at this year’s EADV conference in Milan, with educational activities and a booth to connect with healthcare professionals.At our booth, we spoke with attendees about Medscape and...

Medscape Education Global

- PMLiVE

Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas

Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments.

Avalere Health

- PMLiVE

Arcutis receives FDA approval for steroid-free plaque psoriasis treatment

Zoryve is the first and only PDE4 inhibitor approved for plaque psoriasis

- PMLiVE

Almirall launches call on AlmirallShare to find innovative therapies for skin diseases

Since its launch, the R&D platform has received over 560 proposals from over 50 countries

- PMLiVE

Happify Health and Almirall launch Claro to support psoriasis patients

The digital wellness app is now available to those with the condition living in the UK, Spain and Italy

- PMLiVE

Almirall shares positive topline results from atopic dermatitis trials

The company plans to submit a Marketing Authorisation Application to the EMA later this year

- PMLiVE

Almirall launches Actinic Keratosis Global Day during Skin Cancer Awareness Month

The global event will take place annually on 24 May to increase awareness of skin cancer

- PMLiVE

Almirall and Evotec team up in multi-target dermatology alliance

The companies will focus on developing novel therapies for chronic skin diseases and skin cancer

- PMLiVE

Almirall and Inserm Transfert to develop innovative vitiligo treatments

Vitiligo is a chronic skin condition that affects patients worldwide

- PMLiVE

Bristol Myers Squibb releases positive trial results for plaque psoriasis treatment

Plaque psoriasis is a chronic, systemic immune-mediated disease associated with multiple serious comorbidities

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links